Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Hefeng Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for lincomycin hydrochloride injections. The drug passed the generic drug consistency evaluation. This medicine is suitable for severe infections caused by sensitive strains such as streptococci, pneumococci, and staphylococci, but only for patients who are allergic to penicillin or who are determined by a doctor not to use penicillin.

Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Hefeng Pharmaceutical Co., Ltd., a subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for lincomycin hydrochloride injections. The drug passed the generic drug consistency evaluation. This medicine is suitable for severe infections caused by sensitive strains such as streptococci, pneumococci, and staphylococci, but only for patients who are allergic to penicillin or who are determined by a doctor not to use penicillin.